|keynote 028 trial||0.29||0.4||4316||55|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02054806 Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, van Brummelen E. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.What are the primary endpoints of a clinical trial?
Primary endpoints were safety and tolerability, analysed in the all-patients-as-treated population, and objective response, analysed for the full-analysis set. This trial is registered with ClinicalTrials.gov, number NCT02054806, and is ongoing but not recruiting participants.What are the NCCN guidelines for the treatment of mesothelioma?
NCCN clinical practice guidelines in oncology (NCCN Guidelines): malignant pleural mesothelioma. Alimta (pemetrexed disodium) injection, powder, lyophilized, for solution for intravenous use.